220
Views
2
CrossRef citations to date
0
Altmetric
Patent Evaluations

PSMA-targeted dendrimers: a patent evaluation (WO2012078534)

, MBBS, , MD PhD, , MD & , MD MS
Pages 665-668 | Published online: 13 Apr 2013
 

Abstract

Prostate-specific membrane antigen (PSMA) is a cell surface protein expressed primarily in prostate cancer and solid tumor neovasculature. PSMA has been a target for both imaging and therapeutic investigations due to its increased expression in advanced disease and in prostate cancer patients receiving hormonal therapy. The recent approval of new androgen receptor pathway targeted drugs for prostate cancer has sharply increased this interest in creating novel probes to measure this disease-specific biomarker. Monoclonal antibodies and small molecules targeting PSMA, however, have been investigated for diagnostic and therapeutic purposes, with only limited success. In fact, only one agent (monoclonal antibody agent - capromab pendetide) has been FDA-approved for human use. PSMA-targeting dendrimers may provide a targeting method that might maintain the specificity of monoclonal antibodies, achieve high levels of tumor concentration (similar to small molecule antagonist ligands) and avoid accumulation in non-target sites of PSMA expression (such as renal tubules). The current patent application provides theoretical evidence for the advantage of PSMA-targeting dendrimers with in vitro data for PSMA binding, but lacks sufficient preclinical animal binding, dosimetry and toxicology data.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.